At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01061 ESSEX BIO-TECH
Early Closed 12-24 12:08:29
2.900
-0.050
-1.69%
High2.920
Low2.880
Vol116.00K
Open2.910
D1 Closing2.950
Amplitude1.36%
Mkt Cap1.65B
Tradable Cap1.65B
Total Shares567.29M
T/O336.67K
T/O Rate0.02%
Tradable Shares567.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Essex Bio-Technology - Approval to Commercialise Preservative-Free Unit-Dose Sodium Hyaluronate Eye Drops (0.1%) in China From Nmpa
Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.